Igc Pharma, INC Form 4 insider transactions

IGC Pharma CEO Mukunda Ram converted $601,148 of outstanding debt into 2,226,475 shares of common stock at $0.27 per share.

Claudia Grimaldi, a Director and Officer of IGC Pharma, Inc., acquired 2,048,378 shares of common stock in exchange for canceling $553,062 in outstanding indebtedness.

Director Richard Prins acquired 170,000 shares of IGC Pharma common stock through the vesting and exercise of restricted stock units.

CEO Ram Mukunda increased his stake in IGC Pharma through the exercise of restricted stock units and stock options.

Director James P. Moran acquired 130,000 shares of IGC Pharma common stock through the vesting of restricted stock units.

IGC Pharma Director and PFO Claudia Grimaldi acquired 238,462 shares of common stock through the exercise of RSUs and stock options.

IGC Pharma's CEO, Ram Mukunda, reported his spouse's acquisition of 50,000 common shares and 99,999 restricted stock units.

IGC Pharma Director Richard K. Prins acquired 100,000 shares of common stock through the vesting of Restricted Stock Units on January 19, 2026.

IGC Pharma Director Richard K. Prins was granted 750,000 stock options with an exercise price of $0.35, vesting over three years.

IGC Pharma's Director, James P. Moran, was granted 500,000 stock options with an exercise price of $0.35, vesting over three years.

IGC Pharma, Inc. Director and 10% owner Terry L. Lierman was granted 500,000 stock options exercisable at $0.35, vesting over three years.

IGC Pharma's PFO, Claudia Grimaldi, gifted 50,000 common shares and was granted 1.5 million stock options with varying vesting schedules.

IGC Pharma's CEO, Ram Mukunda, reported gifting 100,000 shares and receiving grants of 4.5 million stock options.

Director James Moran indirectly acquired 588,235 shares of IGC Pharma through Moran Global Strategies, Inc. as part of a share purchase agreement.

Director Richard K. Prins of IGC Pharma, Inc. reports donating 200,000 shares of common stock to the US Charitable Gift Trust on August 12, 2024.

Bradbury Strategic Investment Fund A reports acquiring additional shares of IGC Pharma, Inc. at $0.34 per share, increasing its holdings.

IGC Pharma CEO Ram Mukunda reports acquisition and disposal of common stock and derivative securities, including restricted stock units and options, through various transactions on March 13, 2024.

Director Claudia Grimaldi reports the acquisition of common stock and options in IGC Pharma, Inc. through the vesting of restricted stock units and the grant of new options.

Director Richard Prins reports acquisition of common stock through vesting of restricted stock units.

Director James P. Moran reports acquisition of IGC Pharma shares and restricted stock units (RSUs) through vesting and grants.

Director Terry L. Lierman reports acquisition of options to purchase 150,000 shares of IGC Pharma common stock.